Dr. Reddy’s Laboratories has announced its consolidated financial results for the quarter ended December 31, 2018 under International Financial Reporting Standards (IFRS).
Segmental Analysis
Global Generics (GG)
Revenues from GG segment at `31.3 billion. Year-on-year growth of 4%, primarily driven by contributions from Emerging Markets, India and favorable forex. Sequentially the sales grew by 3%.
G.V. Prasad, CEO and Co-chairman, Dr Reddy’s said, “We continued to improve our performance in the third quarter of FY 19, supported by significant growth in emerging markets and India, pickup in new product launches, and improvements in cost structure. We are on track towards delivering sustainable & profitable growth.”
Income Statement Highlights: